Recombinant human interleukin-1 receptor antagonist for injection

注射用重组人白细胞介素1受体拮抗剂

Report date: 2026/05/20 20:02:01

Base Information

Drug NameRecombinant human interleukin-1 receptor antagonist for injection
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionInterleukin-1 receptor-like 1 inhibitors
TargetsInterleukin-1 receptor-like 1
Therapy Area/IndicationsInflammationKeratoconjunctivitis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesSichuan Hengxing Biomedicine Co LtdXizang Huaxi Pharmaceutical Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesXizang Huaxi Pharmaceutical Group Co LtdSichuan Hengxing Biomedicine Co Ltd
Inactive CompaniesN/A
Active IndicationsInflammationKeratoconjunctivitis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A